Trial · NCT04321395
Vigabatrin and Insulin Sensitivity
NCT04321395, Phase 2, Completed, Washington University School of Medicine; results first posted 2025-01-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Vigabatrin and Insulin Sensitivity. Trials, record NCT04321395. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04321395
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Vigabatrin and Insulin Sensitivity
- NCT number
- NCT04321395
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 4 participants, actual
- Lead sponsor
- Washington University School of Medicine
- Conditions
- NAFLD, Obesity
- Interventions
- Vigabatrin
- First posted
- 2020-03-25
- Last updated
- 2025-01-14
- Results first posted
- 2025-01-14
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Insulin Sensitivity | 3 weeks after initiation of treatment | Measured by hyperglycemic euglycemic clamp |
| Secondary | Oral Glucose Tolerance | 3 weeks after initiation of treatment | Measured by 75 gram oral glucose tolerance test |
| Secondary | Oral Glucose Insulin Sensitivity | After 3 weeks on drug | Insulin sensitivity based on oral glucose tolerance. Values are calculated using glucose and insulin from a 3-hour 75 gram oral glucose tolerance test at 0, 2, and 3 hours. Higher values are indicate better insulin sensitivity. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Insulin Sensitivity | 3 weeks after initiation of treatment | mg/kg FFM/min | MEAN | |
| SECONDARY | Oral Glucose Tolerance | 3 weeks after initiation of treatment | mg/dL | MEAN | |
| SECONDARY | Oral Glucose Insulin Sensitivity | After 3 weeks on drug | ml/min/m^2 of body surface area | MEAN |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Insulin Sensitivity | Vigabatrin | 6.82 | Standard Deviation 1.7 | mg/kg FFM/min | |
| Oral Glucose Tolerance | Vigabatrin | 155.5 | Standard Deviation 19.2 | mg/dL | |
| Oral Glucose Insulin Sensitivity | Vigabatrin | 294 | Standard Deviation 56 | ml/min/m^2 of body surface area |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Vigabatrin | 4 | |
| Overall Study | COMPLETED | Vigabatrin | 4 | |
| Overall Study | NOT COMPLETED | Vigabatrin | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Experimental: Vigabatrin | 0 | 4 |
| Total, other adverse events | Experimental: Vigabatrin | 0 | 4 |
| Total, serious adverse events | Experimental: Vigabatrin | 0 | 4 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04321395
GET https://conductscience.org/api/trials/v1/NCT04321395/registered